title: Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.
abstract: OBJECTIVE
  To assess the influence of preoperative portal vein embolization (PVE) on the long-term outcome of liver resection for colorectal metastases.
  
  
  BACKGROUND
  Preoperative PVE of the liver induces hypertrophy of the remnant liver and increases the safety of hepatectomy.
  
  
  METHODS
  Thirty patients underwent preoperative PVE and 88 patients did not before resection of four or more liver segments. PVE was performed when the estimated rate of remnant functional liver parenchyma (ERRFLP) assessed by CT scan volumetry was less than 40%.
  
  
  RESULTS
  PVE was feasible in all patients. There were no deaths. The complication rate was 3%. The post-PVE ERRFLP was significantly increased compared with the pre-PVE value. Liver resection was performed after PVE in 19 patients (63%), with surgical death and complication rates of 4% and 7% respectively. PVE increased the number of resections of more than four segments by 19% (17/88). Actuarial survival rates after hepatectomy with or without previous PVE were comparable: 81%, 67%, and 40% versus 88%, 61%, and 38% at 1, 3, and 5 years respectively.
  
  
  CONCLUSIONS
  PVE allows more patients with previously unresectable liver tumors to benefit from resection. Long-term survival is comparable to that after resection without PVE.
authors.affiliation: Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, France.
authors.forename: D
authors.initials: D
authors.lastname: Azoulay
authors.forename: D
authors.initials: D
authors.lastname: Castaing
authors.forename: A
authors.initials: A
authors.lastname: Smail
authors.forename: R
authors.initials: R
authors.lastname: Adam
authors.forename: V
authors.initials: V
authors.lastname: Cailliez
authors.forename: A
authors.initials: A
authors.lastname: Laurent
authors.forename: A
authors.initials: A
authors.lastname: Lemoine
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D002955:Leucovorin; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011300:Preoperative Care; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil